Senior VP Intellia Therapeutics Cambridge, Massachusetts, United States
This presentation will be focused on the use of CRISPR/Cas9 genome editing technology to engineer Allogeneic CAR-T as ex vivo cell therapies. Examples will be provided using in vitro and in vivo non-clinical models to demonstrate efficient editing to mitigate host T and NK cell mediated graft rejection and graft vs. host disease (GVHD).
Learning Objectives:
Understand immune response for graft rejection (host T and NK-mediated) and graft vs. host disease (GVHD).
Learn prinicples of CRISPR/Cas9 genome editing based cell engineering
See how different non-clinical models were used to answer the key questions of graft rejection and GVHD
